Nootropic & CNS

A synthetic heptapeptide approved in Russia for stroke and cognitive disorders, studied for BDNF-driven neuroprotection.

A synthetic anxiolytic peptide developed in Russia, studied for anxiety and mild cognitive effects without sedation.

A standardized mixture of neuropeptides used clinically in many countries for stroke, dementia, and TBI.

An experimental angiotensin-derived peptide reported to be an extremely potent promoter of new synapse formation in animal models of cognition.

A small peptide derived from a neurotrophic factor studied for promoting new neuron growth and protecting against Alzheimer-like changes in animals.

An experimental peptide studied for rapid antidepressant effects and neurogenesis by blocking a potassium channel in the brain.

A proline-containing dipeptide nootropic approved in Russia, studied for mild cognitive impairment and neuroprotection.

A naturally occurring peptide studied for sleep, stress resilience, and pain, with limited and inconsistent human evidence.

A neuroprotective peptide fragment studied in humans for neurodegenerative disease, with a failed pivotal trial but ongoing interest.

A peptide derived from a neural cell adhesion molecule studied in animals for memory, plasticity, and neuroprotection.

A mixture of low-molecular-weight brain peptides used in Russia for stroke, brain injury, and cognitive disorders.

A short synthetic peptide bioregulator from the Khavinson group studied for brain protection and cognition.

The first clinical drug from Retro Biosciences, the Sam Altman-backed longevity company: an oral, brain-penetrant molecule meant to restore cellular clean-up (autophagy) for Alzheimer's and Parkinson's, in Phase 1 since December 2025.

Roche's anti-amyloid antibody with a transferrin-receptor 'shuttle' that cleared amyloid in 91% of patients within seven months at a fraction of the ARIA seen with lecanemab or donanemab; Phase 3 started in 2025.

Lilly's next-generation, self-injected successor to donanemab that cleared amyloid in 75% of patients by six months in Phase 1, with a Phase 3 that completed in 2026.

An oral drug that lowers production of amyloid, tau and alpha-synuclein at once, now in an 850-patient Alzheimer's Phase 3 with a symptomatic readout due early 2027.

An oral IGF-1 metabolite mimic from the makers of trofinetide (Daybue), in the first-ever Phase 3 for Phelan-McDermid syndrome since February 2026.

A Salk Institute fisetin derivative described as a 'geroneuroprotector' that improved memory and reduced brain lipid damage in mouse models of Alzheimer's; still in animal toxicology, yet already sold as a research chemical.

A four amino acid Khavinson bioregulator sold as the defined-sequence cousin of Cortexin for brain recovery; animal data from a single St. Petersburg group and no pharmacokinetics for any route.

The wakefulness neuropeptide, sold as a nasal spray for alertness after a primate study showed intranasal delivery reversed sleep-deprivation deficits; no human efficacy trial exists and approved narcolepsy drugs use small molecules instead.

A terminally modified analog of Semax sold as a more stable, longer-acting nasal spray; no published study of the amidate form exists, so its parent's Russian literature cannot be assumed to transfer.

A Russian orally active dipeptide anxiolytic acting on the cholecystokinin system, launched by Western vendors in 2026 as a non-sedating benzodiazepine alternative; single-group animal data only.